[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-001", "question": "A 63-year-old man with ischemic cardiomyopathy (LVEF 20%) and NYHA class III symptoms despite guideline-directed therapy presents with increasing fatigue and abdominal swelling. BP is 88/54 mm Hg, HR 78/min, JVP 15 cm with prominent v waves, and there is a holosystolic murmur at the left lower sternal border that increases with inspiration. Echo shows severe functional tricuspid regurgitation with right atrial and RV dilation, TAPSE 1.0 cm, RV fractional area change 25%, PASP 42 mm Hg, and no significant left-sided valvular disease. Coronary anatomy is unchanged from prior and not revascularizable. He is in sinus rhythm and not a heart transplant candidate. After optimization of diuretics, he remains symptomatic. Which management strategy is most appropriate to improve outcomes?", "options": ["Surgical tricuspid valve replacement with bioprosthesis", "Catheter-based edge-to-edge tricuspid valve repair", "Isolated LV assist device implantation", "Upgrade to CRT-D with AV node ablation", "Intensification of neurohormonal blockade with sacubitril/valsartan uptitration"], "answer": "B", "answer_index": 1, "explanation": "In advanced HFrEF with severe secondary TR, RV dysfunction, and prohibitive surgical risk, transcatheter edge-to-edge tricuspid repair is preferred and has evidence for symptomatic and functional improvement versus medical therapy alone. Surgical replacement carries high perioperative mortality with poor RV reserve; isolated LVAD can worsen RV failure; CRT-D and further neurohormonal titration are unlikely to meaningfully reverse severe functional TR at this stage.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 63-year-old with severe ischemic cardiomyopathy (LVEF 20%), NYHA III symptoms, and severe functional tricuspid regurgitation with RV dysfunction (TAPSE 1.0 cm, FAC 25%). Key discriminating findings include: hypotension (88/54), prominent v waves, inspiratory murmur increase (Carvallo sign), severe TR with RV dilation, poor RV function, and prohibitive surgical risk (low LVEF, poor RV reserve, not transplant candidate). The question asks for optimal management after medical optimization. Option B (transcatheter edge-to-edge repair) is the best answer: TRILUMINATE and other trials demonstrate safety/efficacy in high-risk TR patients, addressing the primary pathology with lower procedural risk. Option A (surgical TVR) carries prohibitive mortality risk given severe biventricular dysfunction and low cardiac output state. Option C (isolated LVAD) risks worsening RV failure and TR. Option D (CRT-D upgrade) is reasonable but won't reverse established severe TR; patient already has sinus rhythm making AV node ablation questionable. Option E (medication uptitration) is unlikely to reverse structural TR after optimization failed. The item is logically valid with clear clinical scenario supporting transcatheter intervention as emerging standard for this population. Medical accuracy is high, reflecting current practice patterns for inoperable severe functional TR. Minimal fix: None needed; item is defensible as written.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 63-year-old with severe ischemic cardiomyopathy (LVEF 20%), NYHA III symptoms, and severe functional tricuspid regurgitation with RV dysfunction (TAPSE 1.0 cm, FAC 25%). Key discriminating findings include: hypotension (88/54), prominent v waves, inspiratory murmur increase (Carvallo sign), severe TR with RV dilation, poor RV function, and prohibitive surgical risk (low LVEF, poor RV reserve, not transplant candidate). The question asks for optimal management after medical optimization. Option B (transcatheter edge-to-edge repair) is the best answer: TRILUMINATE and other trials demonstrate safety/efficacy in high-risk TR patients, addressing the primary pathology with lower procedural risk. Option A (surgical TVR) carries prohibitive mortality risk given severe biventricular dysfunction and low cardiac output state. Option C (isolated LVAD) risks worsening RV failure and TR. Option D (CRT-D upgrade) is reasonable but won't reverse established severe TR; patient already has sinus rhythm making AV node ablation questionable. Option E (medication uptitration) is unlikely to reverse structural TR after optimization failed. The item is logically valid with clear clinical scenario supporting transcatheter intervention as emerging standard for this population. Medical accuracy is high, reflecting current practice patterns for inoperable severe functional TR. Minimal fix: None needed; item is defensible as written.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-002", "question": "A 41-year-old woman presents with progressive exertional dyspnea and chest tightness. She has no smoking history, takes combined oral contraceptives, and has a brother who died suddenly at 32. Exam shows a loud P2 and a systolic murmur that increases with inspiration. ECG shows right axis deviation and incomplete RBBB. Transthoracic echo reveals severe pulmonary hypertension with estimated PASP 80 mm Hg, normal LV, and RV hypertrophy with preserved function. V/Q scan is normal. Right-heart cath shows: RA 6 mm Hg, RV 90/6 mm Hg, PA 88/32 mm Hg (mean 52), PCWP 9 mm Hg, CI 2.1 L/min/m², PVR 10 Wood units. Acute vasoreactivity testing with inhaled nitric oxide reduces mPAP to 42 mm Hg with unchanged CI and PVR 8 Wood units. Genetic testing is pending. What is the most appropriate initial long-term therapy?", "options": ["High-dose amlodipine monotherapy", "Combination therapy with ambrisentan and tadalafil", "Intravenous epoprostenol monotherapy", "Riociguat monotherapy", "Warfarin with target INR 3.0-4.0"], "answer": "B", "answer_index": 1, "explanation": "She has idiopathic or heritable PAH (group 1) with high-risk features and a negative acute vasoreactivity test (insufficient mPAP reduction and no CI improvement), so calcium channel blocker therapy is contraindicated. Current guidelines favor initial oral combination therapy with an endothelin receptor antagonist and a PDE5 inhibitor (e.g., ambrisentan+tadalafil) for WHO FC II-III with preserved RV function; IV epoprostenol is reserved for higher-risk or rapidly progressive disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best choice given the clinical scenario. Key stem clues: 41-year-old woman with severe PAH (PASP 80, mPAP 52, PVR 10 Wood units), family history of sudden death suggesting heritable PAH, high-risk features (CI 2.1, RA 6, RV hypertrophy), and acute vasoreactivity testing showing insufficient response (mPAP reduced to 42 but still >40 mmHg, PVR remains elevated at 8 Wood units, CI unchanged). Main logical issue: The vasoreactivity test is NEGATIVE by standard criteria (requires mPAP ≤40 mmHg or drop >10 mmHg to <40 mmHg with increased/unchanged CO), yet the explanation correctly states CCB is contraindicated. However, this patient has multiple high-risk features: CI 2.1 (low-intermediate risk), elevated RA pressure, and severe hemodynamic compromise. Current ESC/ERS guidelines recommend initial combination therapy for intermediate-high risk PAH, but IV epoprostenol is preferred for high-risk patients. With CI 2.1, RA 6, and severe PVR elevation, this patient meets criteria for high-risk disease requiring IV epoprostenol (option C) rather than oral combination therapy. Medical accuracy: The rationale contradicts risk stratification – these hemodynamics warrant more aggressive therapy. Minimal fix: Modify hemodynamics to show intermediate-risk features (CI >2.5, lower RA pressure) to justify oral combination therapy as the keyed answer.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is not the best choice given the clinical scenario. Key stem clues: 41-year-old woman with severe PAH (PASP 80, mPAP 52, PVR 10 Wood units), family history of sudden death suggesting heritable PAH, high-risk features (CI 2.1, RA 6, RV hypertrophy), and acute vasoreactivity testing showing insufficient response (mPAP reduced to 42 but still >40 mmHg, PVR remains elevated at 8 Wood units, CI unchanged). Main logical issue: The vasoreactivity test is NEGATIVE by standard criteria (requires mPAP ≤40 mmHg or drop >10 mmHg to <40 mmHg with increased/unchanged CO), yet the explanation correctly states CCB is contraindicated. However, this patient has multiple high-risk features: CI 2.1 (low-intermediate risk), elevated RA pressure, and severe hemodynamic compromise. Current ESC/ERS guidelines recommend initial combination therapy for intermediate-high risk PAH, but IV epoprostenol is preferred for high-risk patients. With CI 2.1, RA 6, and severe PVR elevation, this patient meets criteria for high-risk disease requiring IV epoprostenol (option C) rather than oral combination therapy. Medical accuracy: The rationale contradicts risk stratification – these hemodynamics warrant more aggressive therapy. Minimal fix: Modify hemodynamics to show intermediate-risk features (CI >2.5, lower RA pressure) to justify oral combination therapy as the keyed answer.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-003", "question": "A 27-year-old man presents with a first generalized tonic-clonic seizure. MRI brain with and without contrast is normal. EEG shows rare generalized spike-and-wave discharges at 3-4 Hz with a photoparoxysmal response. Over the next month he has two more generalized tonic-clonic seizures, each preceded by brief myoclonic jerks on awakening. He drinks socially and works as a software engineer. He and his partner plan to conceive in the next year, and he wants to avoid cognitive side effects. Which antiepileptic monotherapy is most appropriate?", "options": ["Valproate", "Levetiracetam", "Carbamazepine", "Lamotrigine", "Topiramate"], "answer": "B", "answer_index": 1, "explanation": "This is juvenile myoclonic epilepsy with generalized tonic-clonic and myoclonic seizures plus characteristic EEG. While valproate is highly effective, its teratogenicity, metabolic effects, and cognitive risks make it less desirable in a young adult planning pregnancy with a partner and with concerns about adverse effects. Levetiracetam is effective for generalized epilepsies, has a favorable cognitive profile, and minimal drug interactions; carbamazepine can worsen generalized seizures, and lamotrigine/topiramate are less predictably effective for myoclonus.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes juvenile myoclonic epilepsy (JME): young adult, generalized tonic-clonic seizures, myoclonic jerks on awakening, 3-4 Hz generalized spike-wave on EEG, photoparoxysmal response. Key discriminating findings: male patient planning conception with partner, desires to avoid cognitive side effects. The item attempts to exclude valproate based on teratogenicity concerns, but valproate's teratogenicity primarily affects female patients who become pregnant. For a male patient, valproate remains first-line for JME with superior efficacy over alternatives. The rationale conflates male and female reproductive risks. Lamotrigine is also highly effective for JME, well-tolerated cognitively, and commonly used first-line. Both levetiracetam (keyed answer) and lamotrigine are defensible: levetiracetam has favorable cognitive profile and fewer interactions; lamotrigine has established efficacy for JME with excellent tolerability. The stem does not provide sufficient discriminating features to uniquely favor levetiracetam over lamotrigine. Medical accuracy issue: misapplication of teratogenicity concerns to male patient. Minimal fix: Clarify that the patient's female partner has epilepsy requiring treatment, or specify additional factors (e.g., psychiatric comorbidity, prior lamotrigine failure) that would uniquely favor levetiracetam.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes juvenile myoclonic epilepsy (JME): young adult, generalized tonic-clonic seizures, myoclonic jerks on awakening, 3-4 Hz generalized spike-wave on EEG, photoparoxysmal response. Key discriminating findings: male patient planning conception with partner, desires to avoid cognitive side effects. The item attempts to exclude valproate based on teratogenicity concerns, but valproate's teratogenicity primarily affects female patients who become pregnant. For a male patient, valproate remains first-line for JME with superior efficacy over alternatives. The rationale conflates male and female reproductive risks. Lamotrigine is also highly effective for JME, well-tolerated cognitively, and commonly used first-line. Both levetiracetam (keyed answer) and lamotrigine are defensible: levetiracetam has favorable cognitive profile and fewer interactions; lamotrigine has established efficacy for JME with excellent tolerability. The stem does not provide sufficient discriminating features to uniquely favor levetiracetam over lamotrigine. Medical accuracy issue: misapplication of teratogenicity concerns to male patient. Minimal fix: Clarify that the patient's female partner has epilepsy requiring treatment, or specify additional factors (e.g., psychiatric comorbidity, prior lamotrigine failure) that would uniquely favor levetiracetam.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-004", "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with episodic confusion, sweating, and palpitations occurring mostly late afternoon. Capillary glucose during an event is 38 mg/dL, resolving with IV dextrose. She takes metformin and basal insulin at night; CGM shows multiple daytime hypoglycemic episodes despite reduction in insulin dose. She denies sulfonylurea use or alcohol. Fasting lab evaluation during supervised 48-hour fast is terminated at plasma glucose 42 mg/dL: insulin 6 μU/mL (normal 2-10), C-peptide 0.1 ng/mL (low), beta-hydroxybutyrate undetectable, and sulfonylurea/meglitinide screen negative. CT of the pancreas is normal. What is the most likely diagnosis?", "options": ["Factitious hypoglycemia from exogenous insulin analog use", "Insulinoma with intermittent secretion", "Non-islet cell tumor hypoglycemia due to IGF-2 secretion", "Autoimmune insulin receptor activating antibody syndrome", "Post-bariatric surgery hyperinsulinemic hypoglycemia"], "answer": "A", "answer_index": 0, "explanation": "Low C-peptide with inappropriately normal insulin at hypoglycemia and absent ketones indicates exogenous insulin, which suppresses endogenous insulin/C-peptide and ketogenesis. Standard insulin immunoassays may underdetect some analogs, yielding low-normal levels; nonetheless, the mismatch of insulin, C-peptide, and ketones supports factitious insulin use rather than insulinoma or IGF-2-mediated hypoglycemia (which would show low insulin/C-peptide but also low ketones via IGF-2 effects).", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The stem describes recurrent hypoglycemia in a diabetic patient on insulin therapy. Key discriminating findings during supervised fast at glucose 42 mg/dL are: (1) insulin 6 μU/mL (inappropriately detectable/normal for hypoglycemia), (2) C-peptide 0.1 ng/mL (suppressed), (3) beta-hydroxybutyrate undetectable (ketogenesis suppressed), (4) negative sulfonylurea screen, (5) normal pancreatic CT. The combination of detectable insulin with suppressed C-peptide during hypoglycemia is pathognomonic for exogenous insulin administration—endogenous insulin secretion (insulinoma, sulfonylureas) would elevate both insulin AND C-peptide, while non-insulin hypoglycemia (IGF-2) would suppress both. Absent ketones confirm insulin effect (suppressing lipolysis/ketogenesis). Option A (factitious exogenous insulin) is the unique best answer. Option B (insulinoma) fails because C-peptide would be elevated, not suppressed. Option C (IGF-2) fails because insulin would be suppressed (<2), not 6. Option D (insulin receptor antibodies) would show elevated C-peptide. Option E requires bariatric surgery history (absent). The rationale correctly notes that some insulin analogs may be underdetected by standard assays, explaining the 'low-normal' rather than frankly elevated insulin level. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes recurrent hypoglycemia in a diabetic patient on insulin therapy. Key discriminating findings during supervised fast at glucose 42 mg/dL are: (1) insulin 6 μU/mL (inappropriately detectable/normal for hypoglycemia), (2) C-peptide 0.1 ng/mL (suppressed), (3) beta-hydroxybutyrate undetectable (ketogenesis suppressed), (4) negative sulfonylurea screen, (5) normal pancreatic CT. The combination of detectable insulin with suppressed C-peptide during hypoglycemia is pathognomonic for exogenous insulin administration—endogenous insulin secretion (insulinoma, sulfonylureas) would elevate both insulin AND C-peptide, while non-insulin hypoglycemia (IGF-2) would suppress both. Absent ketones confirm insulin effect (suppressing lipolysis/ketogenesis). Option A (factitious exogenous insulin) is the unique best answer. Option B (insulinoma) fails because C-peptide would be elevated, not suppressed. Option C (IGF-2) fails because insulin would be suppressed (<2), not 6. Option D (insulin receptor antibodies) would show elevated C-peptide. Option E requires bariatric surgery history (absent). The rationale correctly notes that some insulin analogs may be underdetected by standard assays, explaining the 'low-normal' rather than frankly elevated insulin level. No logical flaws or medical inaccuracies present. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-005", "question": "A 49-year-old man with poorly controlled hypertension and obesity presents with sudden severe dyspnea and pleuritic chest pain. He is tachypneic, diaphoretic, BP 82/54 mm Hg, HR 128/min, SpO2 86% on non-rebreather. JVP is 12 cm, lungs are clear. Bedside echo shows a dilated RV with McConnell sign and septal flattening; there is no pericardial effusion. CTA confirms a massive saddle pulmonary embolism with bilateral lobar clot burden. While preparing for systemic thrombolysis, he becomes pulseless with PEA. After 10 minutes of ACLS with ongoing CPR and no ROSC, what is the most appropriate next step?", "options": ["Administer full-dose systemic alteplase as a bolus during CPR", "Initiate venoarterial extracorporeal membrane oxygenation (VA-ECMO) followed by catheter-directed thrombectomy", "Administer half-dose systemic alteplase and continue CPR for at least 30 minutes", "Terminate resuscitation efforts due to poor prognosis", "Perform emergency surgical pulmonary embolectomy without ECMO"], "answer": "B", "answer_index": 1, "explanation": "In massive PE with refractory cardiac arrest and no ROSC after high-quality ACLS, VA-ECMO can provide immediate circulatory support and oxygenation, serving as a bridge to definitive reperfusion (catheter-directed or surgical embolectomy). Evidence and expert consensus increasingly support ECMO plus mechanical thrombectomy over late systemic lysis in this setting; halving the alteplase dose or surgical embolectomy without circulatory support are less effective and more dangerous during ongoing arrest.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 49-year-old man with massive saddle PE confirmed by CTA who develops PEA arrest refractory to 10 minutes of ACLS. Key discriminating findings: (1) confirmed massive PE with hemodynamic collapse, (2) PEA arrest without ROSC after 10 minutes, (3) young patient with reversible cause. The question asks for the most appropriate next step in refractory PE-related cardiac arrest. Option B (VA-ECMO + catheter-directed thrombectomy) is the keyed answer and represents the emerging standard for refractory PE arrest when resources are available—ECMO provides immediate circulatory support while allowing definitive mechanical clot removal. Option A (full-dose alteplase during CPR) is reasonable but less effective than mechanical reperfusion in massive clot burden. Option C (half-dose alteplase) lacks evidence support. Option D (termination) is premature in a young patient with reversible cause and available advanced interventions. Option E (surgical embolectomy without ECMO) has prohibitive mortality during active arrest without circulatory support. The stem provides sufficient detail to identify B as uniquely best in centers with ECMO capability. Medical accuracy: consistent with 2019 ESC guidelines and recent literature supporting ECMO-facilitated interventions for refractory PE arrest. Minimal fix: none needed; item is logically valid and medically sound.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 49-year-old man with massive saddle PE confirmed by CTA who develops PEA arrest refractory to 10 minutes of ACLS. Key discriminating findings: (1) confirmed massive PE with hemodynamic collapse, (2) PEA arrest without ROSC after 10 minutes, (3) young patient with reversible cause. The question asks for the most appropriate next step in refractory PE-related cardiac arrest. Option B (VA-ECMO + catheter-directed thrombectomy) is the keyed answer and represents the emerging standard for refractory PE arrest when resources are available—ECMO provides immediate circulatory support while allowing definitive mechanical clot removal. Option A (full-dose alteplase during CPR) is reasonable but less effective than mechanical reperfusion in massive clot burden. Option C (half-dose alteplase) lacks evidence support. Option D (termination) is premature in a young patient with reversible cause and available advanced interventions. Option E (surgical embolectomy without ECMO) has prohibitive mortality during active arrest without circulatory support. The stem provides sufficient detail to identify B as uniquely best in centers with ECMO capability. Medical accuracy: consistent with 2019 ESC guidelines and recent literature supporting ECMO-facilitated interventions for refractory PE arrest. Minimal fix: none needed; item is logically valid and medically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-006", "question": "A 38-year-old woman presents with progressive proximal muscle weakness over 6 weeks, difficulty climbing stairs, and new-onset dry cough. Exam shows 4/5 strength in hip flexors and shoulder abductors, Gottron papules over MCP joints, and a faint \"mechanic's hands\" rash. CK is 700 IU/L (mildly elevated). High-resolution CT shows bilateral peripheral ground-glass opacities and traction bronchiectasis in lower lobes. Pulmonary function tests show FVC 60% predicted, DLCO 35% predicted, and an FVC/DLCO ratio >1.6. ANA is positive 1:320 speckled. Which specific autoantibody, if present, would indicate the highest risk of rapidly progressive interstitial lung disease requiring aggressive early immunosuppression?", "options": ["Anti-Jo-1 (histidyl-tRNA synthetase)", "Anti-Mi-2", "Anti-MDA5", "Anti-SRP", "Anti-TIF1-γ"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 dermatomyositis is characteristically associated with rapidly progressive, often fatal ILD, even with only mild myositis or CK elevation, and warrants early aggressive combination immunosuppression. Anti-Jo-1 also associates with ILD but usually more indolent; anti-Mi-2 is linked to classic dermatomyositis with good prognosis; anti-SRP to necrotizing myopathy; anti-TIF1-γ to malignancy-associated dermatomyositis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a patient with dermatomyositis (Gottron papules, proximal weakness, elevated CK) and severe interstitial lung disease (ILD) with restrictive pattern (FVC 60%, DLCO 35%, FVC/DLCO >1.6) and imaging showing ground-glass opacities and traction bronchiectasis. The question specifically asks which antibody indicates highest risk of rapidly progressive ILD requiring aggressive immunosuppression. Anti-MDA5 (C) is the correct answer as it is uniquely associated with rapidly progressive, potentially fatal ILD in dermatomyositis, often with minimal muscle involvement (\\\"clinically amyopathic\\\") and only mild CK elevation, matching this presentation. Anti-Jo-1 (A) associates with ILD but typically more indolent/chronic course. Anti-Mi-2 (B) correlates with classic dermatomyositis with favorable prognosis and minimal ILD risk. Anti-SRP (D) causes immune-mediated necrotizing myopathy with severe weakness and very high CK, not ILD. Anti-TIF1-γ (E) associates with malignancy-associated dermatomyositis, not aggressive ILD. The stem provides sufficient discriminating features (severe restrictive ILD, mild myositis, mechanic's hands) that align with anti-MDA5 syndrome. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a patient with dermatomyositis (Gottron papules, proximal weakness, elevated CK) and severe interstitial lung disease (ILD) with restrictive pattern (FVC 60%, DLCO 35%, FVC/DLCO >1.6) and imaging showing ground-glass opacities and traction bronchiectasis. The question specifically asks which antibody indicates highest risk of rapidly progressive ILD requiring aggressive immunosuppression. Anti-MDA5 (C) is the correct answer as it is uniquely associated with rapidly progressive, potentially fatal ILD in dermatomyositis, often with minimal muscle involvement (\"clinically amyopathic\") and only mild CK elevation, matching this presentation. Anti-Jo-1 (A) associates with ILD but typically more indolent/chronic course. Anti-Mi-2 (B) correlates with classic dermatomyositis with favorable prognosis and minimal ILD risk. Anti-SRP (D) causes immune-mediated necrotizing myopathy with severe weakness and very high CK, not ILD. Anti-TIF1-γ (E) associates with malignancy-associated dermatomyositis, not aggressive ILD. The stem provides sufficient discriminating features (severe restrictive ILD, mild myositis, mechanic's hands) that align with anti-MDA5 syndrome. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-007", "question": "A 72-year-old man with long-standing COPD (FEV1 35% predicted), chronic hypercapnia, and recent admission for an acute exacerbation requiring noninvasive ventilation is evaluated 3 weeks after discharge. He continues to have daytime somnolence and morning headaches despite resolution of wheeze and normalization of oxygenation on 2 L/min nasal cannula. ABG on his usual oxygen shows pH 7.37, PaCO2 58 mm Hg, PaO2 70 mm Hg, HCO3- 33 mEq/L. Overnight oximetry reveals sustained hypoventilation with episodic desaturations but no significant obstructive apneas. He is adherent to inhaled therapy and pulmonary rehab. What is the most appropriate next step in chronic management to improve mortality?", "options": ["Increase long-term oxygen therapy to maintain PaO2 >80 mm Hg", "Start nocturnal noninvasive ventilation with targeted normalization of PaCO2", "Add chronic low-dose oral prednisone", "Begin acetazolamide at night to stimulate ventilation", "Switch to high-flow nasal cannula at home during sleep"], "answer": "B", "answer_index": 1, "explanation": "In stable COPD with chronic hypercapnic respiratory failure, particularly after a hypercapnic exacerbation, nocturnal noninvasive ventilation targeting PaCO2 reduction reduces mortality and hospitalizations. Increasing oxygen can worsen hypercapnia; chronic steroids confer harm; acetazolamide has limited long-term data; home high-flow therapy improves comfort but lacks robust mortality benefit compared with NIV in this phenotype.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 72-year-old man with severe COPD (FEV1 35%), chronic hypercapnia (PaCO2 58 mmHg with compensated respiratory acidosis), and persistent symptoms (daytime somnolence, morning headaches) despite optimized medical therapy. Overnight oximetry shows sustained hypoventilation. Key discriminating findings: (1) chronic hypercapnic respiratory failure, (2) recent hospitalization requiring NIV, (3) persistent hypoventilation despite resolution of acute exacerbation, (4) adherence to standard therapy. The question asks for chronic management to improve mortality. Option B (nocturnal NIV targeting PaCO2 normalization) is supported by landmark trials showing mortality benefit in stable COPD with chronic hypercapnic respiratory failure post-exacerbation. Option A is contraindicated—increasing oxygen worsens hypercapnia in CO2 retainers. Option C (chronic steroids) increases harm without mortality benefit in stable COPD. Option D (acetazolamide) lacks robust long-term mortality data in this population. Option E (high-flow nasal cannula) improves comfort but lacks mortality evidence compared to NIV in chronic hypercapnic COPD. The item is medically accurate, reflecting current evidence (e.g., Köhnlein 2014, Murphy 2017 trials). No logical flaws; stem provides sufficient detail for unique best answer selection.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 72-year-old man with severe COPD (FEV1 35%), chronic hypercapnia (PaCO2 58 mmHg with compensated respiratory acidosis), and persistent symptoms (daytime somnolence, morning headaches) despite optimized medical therapy. Overnight oximetry shows sustained hypoventilation. Key discriminating findings: (1) chronic hypercapnic respiratory failure, (2) recent hospitalization requiring NIV, (3) persistent hypoventilation despite resolution of acute exacerbation, (4) adherence to standard therapy. The question asks for chronic management to improve mortality. Option B (nocturnal NIV targeting PaCO2 normalization) is supported by landmark trials showing mortality benefit in stable COPD with chronic hypercapnic respiratory failure post-exacerbation. Option A is contraindicated—increasing oxygen worsens hypercapnia in CO2 retainers. Option C (chronic steroids) increases harm without mortality benefit in stable COPD. Option D (acetazolamide) lacks robust long-term mortality data in this population. Option E (high-flow nasal cannula) improves comfort but lacks mortality evidence compared to NIV in chronic hypercapnic COPD. The item is medically accurate, reflecting current evidence (e.g., Köhnlein 2014, Murphy 2017 trials). No logical flaws; stem provides sufficient detail for unique best answer selection.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-008", "question": "A 59-year-old man with a history of MI and paroxysmal atrial fibrillation presents with acute-onset right eye visual loss described as a \"curtain\" descending over 10 minutes, now partially improved. Exam reveals a right relative afferent pupillary defect and patchy visual field deficit; neurologic exam is otherwise normal. He takes apixaban 5 mg twice daily, metoprolol, and atorvastatin, and reports strict adherence. BP is 130/72 mm Hg. MRI brain with DWI is normal; MRA head/neck shows no large-vessel occlusion or significant carotid stenosis. Fundoscopic exam shows retinal whitening in the inferior arcade consistent with branch retinal artery occlusion (BRAO). Which management strategy is most appropriate regarding his antithrombotic regimen?", "options": ["Continue apixaban and add aspirin 81 mg daily indefinitely", "Switch apixaban to warfarin with target INR 2.5-3.5", "Continue apixaban at the same dose without change", "Increase apixaban dose to 10 mg twice daily for 1 month, then 5 mg twice daily", "Discontinue anticoagulation and use dual antiplatelet therapy for 90 days"], "answer": "C", "answer_index": 2, "explanation": "BRAO in an anticoagulated AF patient is treated as a small ischemic stroke; however, there is no high-level evidence that switching DOACs, adding chronic antiplatelet therapy, or using higher-dose anticoagulation improves outcomes over continuing appropriate-dose DOAC once adherence and dosing are confirmed. Adding aspirin increases bleeding risk without proven benefit; warfarin or dual antiplatelets are not superior for AF-related events when DOAC therapy is adequate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 59-year-old man with paroxysmal AF on appropriate-dose apixaban (5 mg BID) who develops BRAO, a retinal ischemic event. Key discriminating findings: (1) confirmed adherence to therapeutic-dose DOAC, (2) AF as embolic source, (3) normal brain MRI/MRA excluding large-vessel disease, (4) BP controlled. The clinical problem asks optimal antithrombotic management post-BRAO in an adequately anticoagulated AF patient. Choice C (continue current apixaban) is correct: BRAO represents a small ischemic stroke; when adherence/dosing are confirmed appropriate, continuing the same DOAC is standard—no evidence supports switching agents, dose escalation, or adding antiplatelet therapy, which increases bleeding risk without proven benefit. Choice A adds aspirin (increases bleeding without AF benefit). Choice B switches to warfarin with supratherapeutic INR (no superiority, higher bleeding risk). Choice D escalates dose without indication (apixaban 5 mg BID is standard for AF with CrCl >30). Choice E stops anticoagulation (inappropriate for AF stroke prevention). The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current AF stroke management guidelines. Minimal fix: none needed; item is unambiguous and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 59-year-old man with paroxysmal AF on appropriate-dose apixaban (5 mg BID) who develops BRAO, a retinal ischemic event. Key discriminating findings: (1) confirmed adherence to therapeutic-dose DOAC, (2) AF as embolic source, (3) normal brain MRI/MRA excluding large-vessel disease, (4) BP controlled. The clinical problem asks optimal antithrombotic management post-BRAO in an adequately anticoagulated AF patient. Choice C (continue current apixaban) is correct: BRAO represents a small ischemic stroke; when adherence/dosing are confirmed appropriate, continuing the same DOAC is standard—no evidence supports switching agents, dose escalation, or adding antiplatelet therapy, which increases bleeding risk without proven benefit. Choice A adds aspirin (increases bleeding without AF benefit). Choice B switches to warfarin with supratherapeutic INR (no superiority, higher bleeding risk). Choice D escalates dose without indication (apixaban 5 mg BID is standard for AF with CrCl >30). Choice E stops anticoagulation (inappropriate for AF stroke prevention). The item is logically valid with one defensible best answer matching the key. Medical accuracy is high, reflecting current AF stroke management guidelines. Minimal fix: none needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-009", "question": "A 46-year-old man presents with sudden severe tearing chest pain radiating to the back. BP is 210/110 mm Hg in both arms, HR 112/min. CT angiography shows an acute Stanford type B aortic dissection starting distal to the left subclavian artery and extending to the infrarenal aorta with involvement of the origin of the left renal artery, but no signs of rupture or pericardial effusion. The left kidney is perfused via a narrowed true lumen; creatinine is 1.4 mg/dL (baseline 1.0). There is no limb ischemia, mesenteric ischemia, or refractory pain after initial IV beta-blocker and vasodilator therapy, and BP is controlled to 115/70 mm Hg. Which management strategy is most appropriate now?", "options": ["Immediate thoracic endovascular aortic repair (TEVAR) to prevent late aneurysmal degeneration", "Open surgical repair of the descending thoracic aorta due to renal artery involvement", "Strict medical therapy with anti-impulse control and serial imaging", "Prophylactic left renal artery stenting plus medical therapy", "Fenestration and true lumen expansion with balloon angioplasty"], "answer": "C", "answer_index": 2, "explanation": "Uncomplicated type B aortic dissection without rupture, malperfusion, refractory pain, or uncontrolled hypertension is managed initially with aggressive medical therapy and surveillance. Renal artery involvement without clinical malperfusion or progressive renal dysfunction does not mandate immediate TEVAR or intervention; endovascular repair is reserved for complicated cases or aneurysmal progression on follow-up imaging.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a Stanford type B aortic dissection with renal artery involvement but explicitly states no rupture, no limb/mesenteric ischemia, no refractory pain after initial therapy, and successful BP control. The creatinine elevation (1.4 from baseline 1.0) is mild and does not constitute clinical malperfusion requiring urgent intervention. Key discriminating findings: (1) type B dissection, (2) hemodynamically stable after medical therapy, (3) no complications (rupture, malperfusion syndromes, refractory pain/hypertension). Current guidelines classify this as uncomplicated type B dissection, for which strict medical therapy with anti-impulse control (beta-blockers, vasodilators targeting HR <60 and SBP 100-120) plus serial imaging is standard first-line management. Option A (immediate TEVAR) is incorrect—TEVAR in uncomplicated type B does not improve outcomes and is reserved for complicated dissections or late aneurysmal degeneration. Option B (open surgery) carries excessive morbidity without indication. Option D (prophylactic stenting) lacks evidence and risks complications. Option E (fenestration) is for true malperfusion, not present here. The keyed answer C is medically accurate and uniquely defensible. Minimal fix: None needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a Stanford type B aortic dissection with renal artery involvement but explicitly states no rupture, no limb/mesenteric ischemia, no refractory pain after initial therapy, and successful BP control. The creatinine elevation (1.4 from baseline 1.0) is mild and does not constitute clinical malperfusion requiring urgent intervention. Key discriminating findings: (1) type B dissection, (2) hemodynamically stable after medical therapy, (3) no complications (rupture, malperfusion syndromes, refractory pain/hypertension). Current guidelines classify this as uncomplicated type B dissection, for which strict medical therapy with anti-impulse control (beta-blockers, vasodilators targeting HR <60 and SBP 100-120) plus serial imaging is standard first-line management. Option A (immediate TEVAR) is incorrect—TEVAR in uncomplicated type B does not improve outcomes and is reserved for complicated dissections or late aneurysmal degeneration. Option B (open surgery) carries excessive morbidity without indication. Option D (prophylactic stenting) lacks evidence and risks complications. Option E (fenestration) is for true malperfusion, not present here. The keyed answer C is medically accurate and uniquely defensible. Minimal fix: None needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed123-010", "question": "A 24-year-old man presents to the ED after being found confused and agitated. He reports taking an unknown \"research chemical\" for recreation. Vitals: T 40.1°C, HR 146/min, BP 178/104 mm Hg, RR 28/min, SpO2 96% RA. Exam shows mydriasis, diaphoresis, severe agitation with tremor, hyperreflexia, and inducible clonus, but no muscle rigidity. He is not taking prescription drugs and denies MAOI or SSRI use. Labs: Na 138, K 4.1, creatinine 1.0, CK 200 IU/L, normal LFTs. UDS is positive only for amphetamines. Despite high-dose benzodiazepines he remains agitated and hyperthermic. Which is the most appropriate next pharmacologic intervention?", "options": ["Intravenous dantrolene", "Intravenous cyproheptadine via crushed tablets", "Intravenous nitroprusside for blood pressure control alone", "Intravenous dexmedetomidine infusion", "Intravenous bromocriptine"], "answer": "D", "answer_index": 3, "explanation": "This is severe sympathomimetic (likely synthetic stimulant) toxicity with hyperthermia and agitation; there is hyperreflexia but the overall picture and isolated amphetamine screen favor stimulant rather than true serotonin syndrome. When benzodiazepines are insufficient, dexmedetomidine provides sympatholysis and sedation without worsening hyperthermia or respiratory drive as much as deep barbiturate or propofol sedation. Cyproheptadine and dantrolene target serotonin syndrome and NMS, respectively; bromocriptine is used in NMS and would exacerbate sympathomimetic effects.", "generator_model": "gpt-5.1-2025-11-13", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 24-year-old with hyperthermia (40.1°C), severe agitation, mydriasis, diaphoresis, tachycardia, hypertension, hyperreflexia, and inducible clonus after taking an unknown \\\"research chemical.\\\" UDS positive only for amphetamines. The stem explicitly states \\\"hyperreflexia and inducible clonus\\\" which are hallmark features of serotonin syndrome, yet the rationale dismisses this as \\\"stimulant rather than true serotonin syndrome.\\\" This creates ambiguity. Clonus (especially inducible) is NOT typical of pure sympathomimetic toxicity and strongly suggests serotonergic activity. Many synthetic stimulants (bath salts, substituted cathinones) have significant serotonergic effects. The presence of clonus makes cyproheptadine (B) defensible for serotonin syndrome treatment. The rationale's assertion that \\\"isolated amphetamine screen favor stimulant\\\" ignores that many serotonergic research chemicals cross-react with amphetamine immunoassays. Both B (cyproheptadine for serotonin syndrome features) and D (dexmedetomidine for refractory sympathomimetic agitation) are defensible given the mixed clinical picture. Main medical issue: The clinical findings (especially clonus) don't cleanly support dismissing serotonin syndrome. Minimal fix: Remove clonus from exam findings OR clarify the substance class to definitively exclude serotonergic activity.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette describes a 24-year-old with hyperthermia (40.1°C), severe agitation, mydriasis, diaphoresis, tachycardia, hypertension, hyperreflexia, and inducible clonus after taking an unknown \"research chemical.\" UDS positive only for amphetamines. The stem explicitly states \"hyperreflexia and inducible clonus\" which are hallmark features of serotonin syndrome, yet the rationale dismisses this as \"stimulant rather than true serotonin syndrome.\" This creates ambiguity. Clonus (especially inducible) is NOT typical of pure sympathomimetic toxicity and strongly suggests serotonergic activity. Many synthetic stimulants (bath salts, substituted cathinones) have significant serotonergic effects. The presence of clonus makes cyproheptadine (B) defensible for serotonin syndrome treatment. The rationale's assertion that \"isolated amphetamine screen favor stimulant\" ignores that many serotonergic research chemicals cross-react with amphetamine immunoassays. Both B (cyproheptadine for serotonin syndrome features) and D (dexmedetomidine for refractory sympathomimetic agitation) are defensible given the mixed clinical picture. Main medical issue: The clinical findings (especially clonus) don't cleanly support dismissing serotonin syndrome. Minimal fix: Remove clonus from exam findings OR clarify the substance class to definitively exclude serotonergic activity.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]